Raltegravir Pharmacokinetics in Neonates Following Maternal Dosing

類似資料

• IMPACT OF LOW BIRTH WEIGHT AND PREMATURITY ON NEONATAL RALTEGRAVIR PHARMACOKINETICS: IMPAACT P1097
  著者:: Clarke, Diana F., 等
  出版事項: (2020)
• Raltegravir (RAL) in neonates: Dosing, pharmacokinetics (PK), and safety in HIV-1 exposed neonates at risk of infection (IMPAACT P1110)
  著者:: Clarke, Diana F., 等
  出版事項: (2020)
• Maternal–Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
  著者:: Lommerse, Jos, 等
  出版事項: (2019)
• Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age
  著者:: Nachman, Sharon, 等
  出版事項: (2015)
• Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110
  著者:: Clarke, Diana F, 等
  出版事項: (2019)